Nuala Moran

3 days ago | bioworld.com | Nuala Moran

With trade agreement secured, US and UK await section 232 outcomeThe U.K. became the first country to reach agreement with the U.S. over threatened tariffs in an “economic prosperity deal” (EPD) that leaves the pharma industry hanging on for the outcome of the U.S. section 232 probe into the implications of pharmaceutical imports for America’s national security. BioWorld Regulatory Europe U.S.

6 days ago | bioworld.com | Nuala Moran

Home » Swiss biotech: Private investments drive industry growth in 2024 BioWorld briefs for May 8, 2025. BioWorld MedTech briefs for May 8, 2025. The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

1 week ago | bioworld.com | Nuala Moran

Home » Nuevocor draws $45M series B for gene therapy in rare heart disease BioWorld briefs for May 6, 2025. BioWorld MedTech briefs for May 6, 2025. The U.S. FDA has accepted the NDA for an oral formulation of Novo Nordisk A/S’s Wegovy (semaglutide) in treating obesity. If approved, the daily pill will be the... The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...

1 week ago | bioworld.com | Nuala Moran

‘Everything is possible’: Pharmas navigate US market uncertainties“We are prepared for every scenario, even though we don’t know what some of those are.” That sums up the message from executives of Astrazeneca plc, GSK plc and Sanofi SA, when quizzed during presentations of their first-quarter 2025 results this week, about the fallout if pharmaceuticals they import to the U.S. are subject to tariffs. BioWorld Asia Financings Europe U.S. Policy Trade

2 weeks ago | bioworld.com | Nuala Moran

‘Everything is possible’: Pharmas navigate US market uncertainties“We are prepared for every scenario, even though we don’t know what some of those are.” That sums up the message from executives of Astrazeneca plc, GSK plc and Sanofi SA, when quizzed during presentations of their first-quarter 2025 results this week, about the fallout if pharmaceuticals they import to the U.S. are subject to tariffs. BioWorld Financings Europe U.S. Policy Trade